Augustine Therapeutics is Participating at J.P. Morgan's 41st Annual Health Care Conference in San Francisco

16.12.2022

Our CEO, Sylvain Celanire, will be participating in J.P. Morgan's 41st Annual Health Care Conference from January 9th-11th 2023 in San Francisco.

This premier conference is the largest healthcare investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators, and investment community members.

Please reach out to us for arranging 1-1 meetings and learn more about our program targeting HDAC6 inhibition for the treatment of #neuromuscular, and neurodegenerative disorders and beyond.

19/10/2022 Event

Augustine Therapeutics’ leadership team will be attending and presenting at two major conferences in London, UK

12/04/2024 Event

Augustine Therapeutics will be participating in the 24th Bio-Equity Europe

06/05/2024 Event

Augustine Therapeutics will be participating in the 3rd ALS Drug Development Summit on May 21-23, 2024 in Boston, MA

All news articles

A thinline.be | soon production

Wijzig uw cookie voorkeuren

Our CEO, Sylvain Celanire, will be participating in J.P. Morgan's 41st Annual Health Care Conference from January 9th-11th 2023 in San Francisco.

Augustine Therapeutics’ leadership team will be attending and presenting at two major conferences in London, UK

Augustine Therapeutics will be participating in the 24th Bio-Equity Europe

Augustine Therapeutics will be participating in the 3rd ALS Drug Development Summit on May 21-23, 2024 in Boston, MA